Ductal Carcinoma in Situ (DCIS) of the breast: Diagnostic and therapeutic controversies

Journal of the American College of Surgeons

Volumn 192, Issue 2, 2001, Pages 196-214

  Silverstein, Melvin J ^b   Parker, Steve ^b   Grotting, James C ^b   Cote, Richard J ^b   Russell, Christy A ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGESTROL; PROGESTERONE; TAMOXIFEN;

APPETITE DISORDER; ASPIRATION BIOPSY; BREAST BIOPSY; BREAST CARCINOMA; BREAST DUCT; BREAST RECONSTRUCTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOMA IN SITU; CATHETER ABLATION; CHOLECYSTITIS; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG INDICATION; DRUG SAFETY; ENDOMETRIUM CANCER; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; METASTASIS; OSTEOPOROSIS; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS, HORMONAL; AXILLA; BIOPSY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LYMPHATIC METASTASIS; MAMMAPLASTY; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; TAMOXIFEN;

EID: 0035130519     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(00)00791-2     Document Type: Conference Paper

References (62)

1. Cancer Statistics, 2000
2. Preoperative evaluation of abnormal mammographic findings to avoid unnecessary breast biopsy
3. Comparison of the relative incidence of impalpable invasive breast carcinoma and ductal carcinoma in situ in patients older and younger than 50 years of age
4. Positive predictive value of breast biopsy performed as a result of mammography: There is no abrupt change at age 50 years
5. Medical audit of rapid-throughput mammography screening practice: Methodology and results of 27,114 examinations
6. Non-palpable breast tumors: Diagnosis with stereotaxic localization and fine-needle aspiration
7. Non-palpable breast lesions: Stereotaxic fine needle aspiration cytology
8. Percutaneous large-core breast biopsy: A multi-institutional study
9. When is core breast biopsy or fine-needle aspiration not enough?
10. State of the art. A practical approach to minimally invasive breast biopsy
11. Stereotactic breast biopsy of ADH and DCIS lesions: Improved accuracy with the Mammotome
12. Clinical management issues in percutaneous core breast biopsy
13. MR-guided biopsy of suspect breast lesions with a simple stereotaxic add-on device for surface coils
14. 3D Rodeo breast MR imaging of lesions containing ductal carcinoma in situ
15. Percutaneous removal of malignant mammographic lesions at stereotactic vacuum-assisted biopsy
16. Advanced breast biopsy instrumentation: Analysis of published experience
17. Randomized trial overview
18. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
19. Radiotherapy in breast conserving treatment for ductal carcinoma in situ: First results of EORTC randomized phase III trial 10853
20. Pathologic finding from the National Surgical Adjuvant Breast Project (NSABP) Protocol B- 17: Intraductal carcinoma (ductal carcinoma in situ)
21. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17
22. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B- 17: Intraductal carcinoma
23. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial
24. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
25. Side effects of radiation therapy
26. Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer
27. Radiotherapy for early breast cancer: Was a comprehensive overview of trials needed?
28. A prognostic index for ductal carcinoma in situ of the breast
29. Prognostic classification of breast ductal carcinoma in situ
30. Whole organ studies
31. Breast irradiation is unnecessary for widely excised ductal carcinoma in situ (DCIS) of the breast
32. The influence of margin width on local control in patients with ductal carcinoma in situ (DCIS) of the breast
33. Prognostic factors in breast cancer
34. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: An NSABP update
35. Ten-year followup results of the treatment of primary operable breast carcinoma
36. Treatment of curable carcinoma of the breast
37. Patterns of relapse and survival following radical mastectomy
38. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
39. Prognostic significance of cytokeratin-positive breast cancer metastases
40. Detection and significance of occult metastases in node-negative breast cancer
41. Micrometastases to axillary lymph nodes for carcinoma of breast: Detection by immunohistochemistry and prognostic significance
42. Occult axillary lymph node metastases in 'node-negative' breast carcinoma
43. Lymph node micrometastases from breast carcinoma: Reviewing the dilemma
44. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer; findings from national adjuvant breast and bowel project B-17
45. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853
46. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program
47. Sentinel node biopsy in ductal carcinoma in situ patients
48. In situ breast carcinoma
49. Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999
50. Importance of lymphatic mapping in ductal carcinoma in-situ (DCIS)
51. Sentinel node biopsy is indicated in breast cancer patients with high-risk DCIS or microinvasion
52. Minimal solid tumor involvement of regional and distant sites
53. Prescribing hormone replacement therapy for menopausal symptoms
54. Megestrol acetate for the prevention of hot flashes
55. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Urogenital atrophy, vasomotor instability, sleep disorders, and related symptoms
56. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Prevention of osteoporosis and CV effects of estrogens and antiestrogens
57. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ Progesterone Replacement Study (HERS) Research Group
58. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
59. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
60. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
61. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
62. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin